Mirabella Financial Services LLP Acquires 3,078 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Mirabella Financial Services LLP grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 133.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,377 shares of the pharmaceutical company’s stock after buying an additional 3,078 shares during the period. Mirabella Financial Services LLP’s holdings in Vertex Pharmaceuticals were worth $2,102,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Vertex Pharmaceuticals by 1.0% in the third quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock valued at $9,484,293,000 after acquiring an additional 243,088 shares in the last quarter. Capital Research Global Investors increased its position in Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Capital Research Global Investors now owns 16,553,281 shares of the pharmaceutical company’s stock valued at $6,482,978,000 after purchasing an additional 444,990 shares during the period. Capital International Investors raised its holdings in Vertex Pharmaceuticals by 77.9% in the 3rd quarter. Capital International Investors now owns 4,689,059 shares of the pharmaceutical company’s stock worth $1,836,550,000 after purchasing an additional 2,053,156 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Vertex Pharmaceuticals by 3.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,522,586 shares of the pharmaceutical company’s stock worth $1,771,226,000 after purchasing an additional 144,266 shares in the last quarter. Finally, Loomis Sayles & Co. L P lifted its position in shares of Vertex Pharmaceuticals by 1.7% in the 2nd quarter. Loomis Sayles & Co. L P now owns 3,813,378 shares of the pharmaceutical company’s stock worth $1,697,716,000 after purchasing an additional 65,047 shares during the period. Institutional investors own 90.96% of the company’s stock.

Insider Activity

In related news, EVP Duncan Mckechnie sold 4,910 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total value of $2,394,361.50. Following the sale, the executive vice president owned 17,559 shares in the company, valued at $8,562,646.35. This represents a 21.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CMO Carmen Bozic sold 2,329 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $481.79, for a total value of $1,122,088.91. Following the transaction, the chief marketing officer directly owned 35,405 shares of the company’s stock, valued at approximately $17,057,774.95. This trade represents a 6.17% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 93,485 shares of company stock valued at $43,967,586. 0.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on VRTX shares. Wolfe Research upgraded shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price target on the stock in a research report on Tuesday, January 6th. Truist Financial raised their price objective on shares of Vertex Pharmaceuticals from $490.00 to $525.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Leerink Partners lifted their price objective on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research report on Monday, December 29th. HC Wainwright upped their target price on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $577.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Twenty-four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $554.30.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $451.59 on Thursday. The company has a 50-day moving average of $469.60 and a 200 day moving average of $439.57. The firm has a market cap of $114.72 billion, a price-to-earnings ratio of 29.46, a PEG ratio of 1.97 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $515.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.98 EPS. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.